On January 18, expert teams including Dr. Gina Jiang, Director of the Hong Kong Institute of Biotechnology (HKIB); Dr. C.K. Wong, Deputy General Manager of Hong Kong Institute of Biotechnology Limited; Shen Hao, Chief Scientific Officer of Fosun Kite Biotechnology Co., Ltd.; and Professor Chen Junhui, Director of the Interventional and Cell Therapy Center at Peking University Shenzhen Hospital, visited Shenzhen Cell Valley for exchange. Shenzhen Cell Valley's Chairman and General Manager Professor Shi Yuanyuan, Chief Scientist Professor Wang Jianxun, Deputy Directors of the Marketing Department Sun Rui and Yang Jianglong, Assistant to the Chairman Wei Zheng, and Director of the General Office Luan Zhishi warmly received them and conducted in-depth discussions on the collaborative development of the cell and gene therapy industry.

Accompanied by Chairman Shi Yuanyuan and guided by his explanations, the visiting experts toured the Shenzhen Cell Valley Smart Exhibition Hall, production workshops, and R&D laboratories, gaining further understanding of the company's development history, core team, the advantages of retroviral vectors for preparing cell therapy products, the four major service platforms — viral products, cell products, regulatory submission assistance, and talent cultivation, GMP-grade production facilities, clinical application progress, major technological breakthroughs, and overall corporate strength.

During the symposium,Chairman Shi Yuanyuan extended a warm welcome to the guests and proposed that Shenzhen Cell Valley will join hands with HKIB, Fosun Kite, and Peking University Shenzhen Hospital to integrate the advantageous resources of leading enterprises, medical institutions, research institutes, and industrial service infrastructure CRO/CDMO platforms. In particular, given the unique geographical advantages and supportive policies of Shenzhen and Hong Kong, a Shenzhen-Hong Kong cooperation demonstration project should be created to jointly build an innovative model and mechanism for cell therapy. Dr. Gina Jiang, Director of HKIB, introduced that the Hong Kong Hospital Authority has commissioned HKIB to build Hong Kong's first cell GMP preparation laboratory, and it is expected that cell therapy products manufactured locally in Hong Kong will enter clinical trials in the first half of this year. Dr. Shen Hao, CSO of Fosun Kite, mentioned that Yikaida, the first cell therapy drug approved in Mainland China, has just received approval from the Hong Kong government, becoming the second CAR-T drug available for use in Hong Kong. Professor Chen Junhui from Peking University Shenzhen Hospital stated that the hospital has extensive experience in IIT and IND clinical studies for both hematological and solid tumors. Dr. Shi Yuanyuan introduced recent major breakthroughs made by Shenzhen Cell Valley in the production and preparation of CAR-NK and CAR-γδT cells, and stated that with policy and market demand support, cell therapy, as a key field of future medicine, is driving Shenzhen Cell Valley to deepen industry-academia-research collaboration, commit to building an open platform, and cooperate with outstanding domestic and international teams and enterprises to promote the development of the cell and gene therapy industry chain.

All participating parties conducted detailed and in-depth exchanges on recent research progress and achievements in cell therapy products, core technologies and advantages, basic and clinical research, and corporate construction and development, laying a solid foundation for exploring cooperation models and future close collaboration. All parties unanimously agreed to rapidly advance cooperation, striving to break through bottlenecks in the industrialization and internationalization of cell therapy in Mainland China and Hong Kong, and explore a new development path for China's CGT industry.